Transcutaneous Acupoint Electrical Stimulation and Postoperative Delirium Delirium

Launched by QIN ZHANG · Mar 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a treatment called transcutaneous acupoint electrical stimulation (TAES) might help prevent or reduce delirium after lung surgery. Delirium is a serious condition that can cause confusion and changes in awareness, especially in older patients after surgery. The trial will involve patients aged 18 and older who are scheduled for a specific type of surgery called thoracoscopic lung resection. Researchers want to see if those who receive TAES before their surgery recover better than those who do not receive this treatment.

To participate in this study, patients should be generally healthy (with some exceptions) and not have severe mental or physical health issues. Participants will be asked to voluntarily join and will be closely monitored during their recovery to see how well they do after surgery. This trial is important because it may help doctors understand how TAES works and whether it can be a useful tool in improving recovery from surgery and reducing the risk of delirium.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntary participation in the study;
• • 2. Age ≥ 18 years;
• • 3. Patients scheduled for thoracoscopic lung resection surgery;
• • 4. ASA grade I-III.
• Exclusion Criteria:
• • 1. History of severe central nervous system diseases, psychiatric disorders, cognitive impairment, intellectual disability, or Mini-Mental State Examination (MMSE) score ≤23;
• • 2. History of opioid addiction, long-term use of analgesic drugs, or psychotropic drugs;
• • 3. Severe cardiovascular and cerebrovascular diseases;
• • 4. Severe liver and kidney dysfunction: Child-Pugh grade B, C patients, patients requiring regular dialysis, etc.;
• • 5. Pregnant or postpartum women;
• • 6. Patients with language communication barriers;
• • 7. Deemed unsuitable for participation by the researchers.